Cargando…

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chung-Shien, Sharma, Sandhya, Miao, Emily, Mensah, Cheryl, Sullivan, Kevin, Seetharamu, Nagashree
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548332/ https://www.ncbi.nlm.nih.gov/pubmed/33117017 http://dx.doi.org/10.2147/LCTT.S258444

Ejemplares similares

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer
por: Wang, Kevin Y, et al.
Publicado: (2021)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu, Nagashree, et al.
Publicado: (2017)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab
por: Lee, Matthew, et al.
Publicado: (2019)

Disparities in lung cancer screening rates among the Hispanic/LatinX population
por: Olazagasti, Coral, et al.
Publicado: (2021)

Disparities in Lung Cancer Screening in Puerto Rico: A United States Colony with Unequal Benefits
por: Olazagasti, Coral, et al.
Publicado: (2021)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Lung cancer screening guidelines are clear but are they being followed?
por: Olazagasti, Coral, et al.
Publicado: (2020)

Impact of Family and Social Network on Tobacco Cessation Amongst Cancer Patients
por: Neumann, Melissa, et al.
Publicado: (2021)

One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population
por: Olazagasti, Coral, et al.
Publicado: (2022)

SAT-LB102 When the Answer Is Not in the First Look: An Unusual Presentation of Follicular Thyroid Carcinoma
por: Bernabe Ramirez, Carolina, et al.
Publicado: (2019)

Efficacy of ketamine mouthwash in the management of oral and pharyngeal toxicity associated with head and neck chemoradiotherapy: protocol for a phase II, Simon’s two-stage trial
por: Koffler, Daniel, et al.
Publicado: (2023)

Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities
por: Dsouza, Philomena Charlotte, et al.
Publicado: (2017)

Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer
por: Newman, James, et al.
Publicado: (2020)

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies
por: Olazagasti, Coral, et al.
Publicado: (2020)

Implementing physician education to increase lung cancer screening uptake
por: Olazagasti, Coral, et al.
Publicado: (2023)

A contemporary snippet on clinical presentation and management of toxic epidermal necrolysis
por: Naik, Piyu Parth
Publicado: (2022)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
por: Runcie, Karie, et al.
Publicado: (2018)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review
por: McGovern, Kerri, et al.
Publicado: (2019)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Missed Opportunities? An Observational Analysis of Lung Cancer Screening Utilization Amongst Patients With Lung Cancer
por: Olazagasti, Coral, et al.
Publicado: (2022)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
por: Udupa, Karthik S, et al.
Publicado: (2017)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
por: Jiang, Shirley Xue, et al.
Publicado: (2019)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Masago, Katsuhiro, et al.
Publicado: (2018)

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
por: Nagano, Tatsuya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cio9invg4ejg4vgi0ioa77052l